InflaRx Reports FY25 Results, Extends Cash Runway to Mid-2027, and Prioritizes Izicopan Development

summarizeSummary

InflaRx reported full-year 2025 results, extended its cash runway to mid-2027, and announced a strategic focus on izicopan development after positive Phase 2a clinical data.

check_boxKey Events

• Cash Runway Extended to Mid-2027

  InflaRx reported €46.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which is expected to fund ongoing operations to mid-2027.

• Strategic Focus on Izicopan Development

  The company is prioritizing izicopan development, particularly for hidradenitis suppurativa (HS), following positive Phase 2a data and is in active discussions with the FDA for Phase 2b trial design.

• GOHIBIC Commercialization Scaled Back

  InflaRx significantly reduced GOHIBIC (vilobelimab) commercial spending and fully wrote down €4.0 million in related inventory, shifting away from active commercialization efforts.

• Full Year 2025 Financial Results

  The company reported a net loss of €45.6 million for 2025, a slight improvement from €46.1 million in 2024, with very low revenue of €29,331.

auto_awesomeAnalysis

InflaRx N.V. has reported its full-year 2025 financial results, highlighting a strategic shift to focus resources on its lead asset, izicopan, following promising Phase 2a data in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). Critically, the company has extended its cash runway to mid-2027, a significant achievement for a small biotech, providing crucial operational stability. This extension is supported by cost reductions, including a substantial write-down of GOHIBIC inventory, and proceeds from recent financing activities. While the company continues to face low revenue and net losses, the clear strategic focus on izicopan and the extended financial runway are important steps in addressing its challenges and advancing its most promising pipeline candidate.